24/7 QualityMeds Blog – Access to Medicines & Healthcare Updates in India

Balanced nutrition and food choices during Ivonescimab treatment What if your plate could tell you what your body needs during Ivonescimab therapy ? Diet is not just about eating healthy but taking the nutrition in a proportionate amount. Do not go behind the magical or fancy Ivonescimab diet, instead try to explore what your plate can actually do? What does your plate reveal? Have a look at your plate and ask yourself whether you are including proteins, fruits, vegetables and sufficient fluids in the right proportions for your needs. Rather than focusing on following a strict or complicated diet, your everyday plate can be a simple way to look at what you are eating during treatment. Nutritional needs in a cancer patient are based on your cancer, treatment combination, appetite, weight and other comorbidities. This means there is no single plate or eating pattern that will work in exactly the same way for everyone. What feels appropriate for one person may not necessarily be suitable...

Inavolisib (Itovebi) 3 mg and 9 mg tablets for PIK3CA-mutated breast cancer treatment. Every patient is different in responding to the same treatment. For some, it may show good therapeutic effects to some; for others, it may lead to harmful events. While the positive outcomes are widely recognised, this article focuses on the most overlooked adverse events.  Understanding Inavolisib’s (Itovebi) Action PIK3CA is a gene that provides instructions for making a part of an enzyme called PI3K. When a mutation occurs in the PIK3CA gene, the PI3K pathway can become overactive, which may encourage breast cancer cells to grow and survive. Inavolisib , the active ingredient in Itovebi, works by targeting the effects of the abnormal PIK3CA mutation and helping slow down the growth and spread of cancer cells. Inavolisib is used in combination with palbociclib and fulvestrant to treat adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast...

Belzutifan 40 mg tablets in India For individuals diagnosed with rare hereditary cancers or advanced kidney cancer, timely access to innovative therapies can play an important role in treatment planning. While new targeted medicines continue to expand treatment possibilities, they are not always immediately available in every country following international approvals. Regulatory timelines, commercial launch schedules and local registration processes may delay patient access, even when a treating physician believes a therapy may be clinically appropriate. Belzutifan is one such targeted therapy that has gained attention for its novel mechanism of action and its role in managing specific tumour types associated with von Hippel-Lindau (VHL) disease and advanced renal cell carcinoma (RCC). For eligible patients living in regions where the medicine has not yet been commercially introduced, regulated Named Patient Programs (NPPs) may provide a pathway for physician-directed access while c...

  Canakinumab (150 mg/ml) injection available in India online For individuals living with rare autoinflammatory disorders, obtaining the right treatment can involve more than receiving a prescription. Some advanced biologic medicines are not routinely supplied through India's regular pharmaceutical distribution network, making regulated international procurement an important option for eligible patients. Canakinumab ( Ilaris ) is one such medicine. While the import process involves several administrative and regulatory steps, understanding the pathway can help patients and caregivers prepare for treatment with greater confidence. When Importing Becomes Necessary Canakinumab is not a medicine that is typically found in retail pharmacies or stocked by most healthcare facilities. As a highly specialized biologic intended for rare inflammatory disorders, its availability depends on controlled procurement rather than routine commercial distribution. Patients who require this therapy t...

Ojjaara (Momelotinib) 100 mg tablets available Online in India For patients living with intermediate or high-risk myelofibrosis accompanied by anemia, access to innovative therapies can significantly influence treatment outcomes. Ojjaara or Momelotinib , developed by GlaxoSmithKline (GSK), is one such advancement that has gained regulatory approvals in the United States and Europe for treating adults with myelofibrosis and anemia. The medication is specifically indicated for patients with primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. The FDA-approved prescribing information recommends a standard dosage of 200 mg once daily and confirms its availability in 100 mg, 150 mg and 200 mg tablet strengths. Despite its international approvals, many patients in India wonder about Ojjaara's availability locally and how they can legally obtain it. Understanding the regulatory process can help patients and caregivers access the me...

Tafasitamab-cxix (Monjuvi) 200 mg in India Monjuvi (  Tafasitamab-cxix  ) has emerged as an important treatment option in certain B-cell lymphomas, offering a targeted approach that differs from traditional cancer therapies. Understanding how this medication works, who may benefit from it, and what to expect during treatment can help patients and caregivers make informed decisions. Here are six important facts about Monjuvi therapy. Monjuvi Is Not Traditional Chemotherapy Cancer treatment is no longer limited to conventional chemotherapy alone. Advances in precision medicine have enabled therapies that focus on specific disease-related targets. Monjuvi is one such treatment, designed to recognize a particular marker found on certain lymphoma cells. This targeted approach allows treatment to be tailored according to disease characteristics and individual patient needs while minimizing effects on normal healthy cells. 1. Monjuvi Is Intended for Specific Lymphoma Patients Monjuvi...

Taletrectinib(Ibtrozi) 200 mg Capsules available in India Many patients assume that follow-up appointments become less important once symptoms improve or treatment appears to be working. However, regular monitoring remains an essential part of cancer care during Ibtrozi (Taletrectinib) therapy. These visits help healthcare professionals evaluate treatment effectiveness, identify potential concerns early, and make informed decisions throughout the treatment journey. 1. Individualized Treatment Assessment No two patients respond to cancer treatment in exactly the same way. Factors such as overall health, disease characteristics, treatment tolerance, and response patterns can vary considerably between individuals. Scheduled follow-up visits allow oncologists to assess these factors and determine whether the current treatment approach continues to meet the patient's clinical needs. 2. Monitoring Disease Status Cancer activity cannot always be determined by symptoms alone. In some case...

Introduction to Vitrakvi (Larotrectinib) What is Vitrakvi? Vitrakvi is the brand name for larotrectinib. It is a highly selective medication used to treat various types of cancer. It belongs to a class of drugs known as kinase inhibitors. Understanding Larotrectinib How it works in the body - Larotrectinib functions by inhibiting tropomyosin receptor kinases (TRK), specifically the TrkA, TrkB, and TrkC proteins. These proteins are encoded by the genes NTRK1, NTRK2, and NTRK3. When these genes fuse with other unrelated genes, they create TRK fusion proteins that act as oncogenic drivers, causing cancer cells to grow and survive uncontrollably. Larotrectinib blocks these signals to stop tumor progression. Targeted cancer therapy explained simply- Unlike traditional chemotherapy that affects many types of cells, larotrectinib is a targeted therapy. It targets a specific genetic mutation (NTRK gene fusion) regardless of where the cancer originated in the body (such as the lungs, thyroid,...

Blinatumomab (Blincyto) in India Blincyto is a Bispecific T-cell engager (BiTE) immunotherapy used for the treatment of certain B-cell precursor acute lymphoblastic leukemia (ALL). Since it works differently from chemotherapy, it has led to curiosity and confusion. These confusions lead to misconceptions to patients, so here’s the article to burst the myth and present the facts. MYTH: Blincyto ( Blinatumomab ) works for all types of leukemia FACT: Blincyto is indicated in adults and children above one month old with: CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.   Relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL).  CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy.  MYTH: Side-effects of Blincyto are sam...